We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+18.15%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
-$36.8M
Cap. Flow
-$162M
Cap. Flow %
-10.58%
Top 10 Hldgs %
64.78%
Holding
69
New
17
Increased
8
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$125M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$49M
3
IDXX icon
Idexx Laboratories
IDXX
+$33.9M
4
EXEL icon
Exelixis
EXEL
+$33.3M
5
BSX icon
Boston Scientific
BSX
+$31.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$84M
2
LLY icon
Eli Lilly
LLY
+$47.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.6M
4
BIIB icon
Biogen
BIIB
+$36.9M
5
MRK icon
Merck
MRK
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$300M 19.62%
1,381,149
-391,975
-22% -$84M
NTRA icon
2
Natera
NTRA
$37.5B
$151M 9.88%
3,100,560
– –
AZN icon
3
AstraZeneca
AZN
$263B
$121M 7.96%
+848,759
New +$125M
ISRG icon
4
Intuitive Surgical
ISRG
$121B
$68.8M 4.51%
201,182
+51,593
+34% +$15.6M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$67.3M 4.41%
754,032
– –
JBIO
6
Jade Biosciences
JBIO
$1.22B
$64.5M 4.22%
107,391
– –
MRK icon
7
Merck
MRK
$324B
$60.9M 3.99%
527,373
-314,149
-37% -$35.7M
VERA icon
8
Vera Therapeutics
VERA
$2.54B
$55.6M 3.64%
3,467,156
– –
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$121B
$51.1M 3.35%
+145,300
New +$49M
EXEL icon
10
Exelixis
EXEL
$13.9B
$48.9M 3.21%
2,560,738
+1,729,495
+208% +$33.3M
DXCM icon
11
DexCom
DXCM
$27.6B
$47.6M 3.12%
370,720
+113,493
+44% +$13.7M
IDXX icon
12
Idexx Laboratories
IDXX
$42.9B
$35.5M 2.32%
+70,674
New +$33.9M
IMTX icon
13
Immatics
IMTX
$1.24B
$35.1M 2.3%
3,041,487
-91,207
-3% -$851K
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.84B
$33.1M 2.17%
1,582,291
+506,867
+47% +$10.6M
BSX icon
15
Boston Scientific
BSX
$65.8B
$32.9M 2.16%
+608,861
New +$31.8M
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$32.9M 2.15%
322,471
-305,212
-49% -$28.9M
CYTK icon
17
Cytokinetics
CYTK
$11B
$27.5M 1.8%
843,228
+489,432
+138% +$18.1M
INBX
18
DELISTED
Inhibrx, Inc. Common Stock
INBX
$25.9M 1.7%
998,283
-246,205
-20% -$5.75M
ZNTL icon
19
Zentalis Pharmaceuticals
ZNTL
$308M
$23.4M 1.53%
828,005
-611,057
-42% -$14.7M
INZY
20
DELISTED
Inozyme Pharma
INZY
$20.4M 1.33%
3,655,308
– –
GERN icon
21
Geron
GERN
$911M
$17.4M 1.14%
5,429,155
-2,845,737
-34% -$8.1M
BAX icon
22
Baxter International
BAX
$11.6B
$16.5M 1.08%
+362,200
New +$15.8M
IDYA icon
23
IDEAYA Biosciences
IDYA
$3.41B
$15.6M 1.02%
664,746
+211,597
+47% +$4.35M
IMGN
24
DELISTED
Immunogen Inc
IMGN
$15.6M 1.02%
827,318
-97,214
-11% -$1.15M
ARGX icon
25
argenx
ARGX
$57.4B
$15.6M 1.02%
+39,921
New +$15.7M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2023 Portfolio in Review

As of Q2 2023, Sofinnova Investments held 69 positions worth $1.53B, down 2.4% from $1.56B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $162M in Q2 2023, closing 17 positions and reducing 13 holdings. Its most notable exit was Eli Lilly, an estimated $47.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in AstraZeneca worth $121M.

  • Sofinnova Investments's largest Q2 2023 buy was AstraZeneca: 848,759 shares worth $121M.
  • Sofinnova Investments added most to Exelixis in Q2 2023, an estimated $33.3M increase.
  • Sofinnova Investments's biggest Q2 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $84M.
  • Sofinnova Investments fully exited Eli Lilly in Q2 2023, selling an estimated $47.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.53B portfolio in Q2 2023.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q2 2023.
  • Sofinnova Investments's portfolio value fell 2.4% quarter-over-quarter to $1.53B.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.